Health Care Resource Use and Costs for Crohn’s Disease before and after Infliximab Therapy
BACKGROUND: Infliximab therapy in patients with Crohn’s disease decreases resource use; however, the overall impact on health-related expenditures is unclear, especially beyond one year of study.
Saved in:
Main Authors: | Dustin E Loomes, Christopher Teshima, Philip Jacobs, Richard Fedorak |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2011-01-01
|
Series: | Canadian Journal of Gastroenterology |
Online Access: | http://dx.doi.org/10.1155/2011/157604 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Does Smoking Reduce Infliximab’s Effectiveness against Crohn’s Disease?
by: Neeraj Narula, et al.
Published: (2009-01-01) -
Improvement of Lumbar Bone Mass after Infliximab Therapy in Crohn’s Disease Patients
by: Marina Mauro, et al.
Published: (2007-01-01) -
Exclusive Enteral Nutrition versus Infliximab in Inducing Therapy of Pediatric Crohn’s Disease
by: Youyou Luo, et al.
Published: (2017-01-01) -
Funding the New Biologics – CCOHTA Report on the Cost Effectiveness of Infliximab for Crohn’s Disease: Pearls and Pitfalls
by: John K Marshall
Published: (2002-01-01) -
Canadian Association of Gastroenterology Clinical Practice Guidelines: The Use of Infliximab in Crohn's Disease
by: Remo Panaccione, et al.
Published: (2004-01-01)